Below are the most recent publications written about "Cytoreduction Surgical Procedures" by people in Profiles.
-
Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, M?enp?? J, Willmott L, Colombo N, Thomes-Pepin J, Liontos M, Gold MA, Garcia Y, Sharma SK, Darus CJ, Aghajanian C, Okamoto A, Wu X, Safin R, Wu F, Molinero L, Maiya V, Khor VK, Lin YG, Pignata S. Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). J Clin Oncol. 2021 06 10; 39(17):1842-1855.
-
Wiseman JT, Abdel-Misih S, Beal EW, Zaidi MY, Staley CA, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Eng O, Fackche N, Greer J, Pawlik TM, Cloyd JM. A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. Surg Oncol. 2021 Jun; 37:101492.
-
Zager Y, Hoffman A, Dreznik Y, Jacoby H, Cordoba M, Horesh N, Nevler A, Gutman M, Berger Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer: The prognostic impact of baseline neutrophil-lymphocyte, platelet-lymphocyte and lymphocyte-monocyte ratios. Surg Oncol. 2020 Dec; 35:321-327.
-
Wiseman JT, Cloyd JM. ASO Author Reflections: Impact of Operative Technique on Anastomotic Failure During Cytoreductive Surgery for Peritoneal Malignancies-Surgeon Preference is Fine. Ann Surg Oncol. 2020 Mar; 27(3):793-794.
-
Wiseman JT, Kimbrough C, Beal EW, Zaidi MY, Staley CA, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Lee B, Fackche N, Greer J, Pawlik TM, Abdel-Misih S, Cloyd JM. Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter? Ann Surg Oncol. 2020 Mar; 27(3):783-792.
-
Chouliaras K, Senehi R, Ethun CG, Poultsides G, Tran T, Grignol V, Gamblin TC, Roggin KK, Tseng J, Fields RC, Weber SM, Russell GB, Levine EA, Cardona K, Votanopoulos K. Recurrence patterns after resection of retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative. J Surg Oncol. 2019 Sep; 120(3):340-347.
-
Zaidi MY, Ethun CG, Liu Y, Poultsides G, Howard JH, Mogal H, Tseng J, Votanopoulos K, Fields RC, Cardona K. The impact of unplanned excisions of truncal/extremity soft tissue sarcomas: A multi-institutional propensity score analysis from the US Sarcoma Collaborative. J Surg Oncol. 2019 Sep; 120(3):332-339.
-
Berger Y, Jacoby H, Zager Y, Lebedyev A, Gutman M, Hoffman A. [CYTOREDUCTIVE SURGERY AND HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY FOR PERITONEAL CARCINOMATOSIS OF COLORECTAL ORIGIN - FIRST 100 CASES]. Harefuah. 2019 Apr; 158(4):227-232.
-
Trieu V, Aulet RM, Ciolino A, Rimash T. SMARCB1-Deficient Sinonasal Carcinoma: A Case Report and Discussion of the Clinical Implications. Ann Otol Rhinol Laryngol. 2019 Jul; 128(7):676-680.
-
Massari F, Di Nunno V, Santoni M, Gatto L, Mollica V, Porta C. Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. Eur Urol Oncol. 2019 09; 2(5):603-604.